BioDelivery Sciences International Inc. settled a lawsuit over the patents for one of its drugs with Teva Pharmaceuticals USA and Teva Pharmaceuticals Industries, according to filing from the Securities and Exchange Commission on Tuesday.

The settlement resolves BioDelivery’s previously reported Belbuca patent litigation against Teva in the U.S. District Court for the District of Delaware.

As part of the settlement agreement, BioDelivery has entered into a license agreement that permits Teva to first begin selling the generic version in the U.S. on Jan 23, 2027.

“We believe this settlement will provide additional certainty around our patent portfolio and the future potential for our two commercialized products,” said CEO Dr. Mark Sirgo.

Belbuca, formally known as Buprenorphine, is an opioid medication used to treat narcotic addiction.

BioDelivery alleged in the lawsuit that the generic form of Belbuca, which Teva is seeking approval to market in the United States, infringed upon two U.S. patents owned by BioDelivery.

BioDelivery is a specialty pharmaceutical company with a focus in the areas of pain management and addition medicine.

BioDelivery’s shares rose 5 cents to $2.30 in Tuesday trading.